Logo

ENLV

Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd. • NASDAQ
$0.97 ▲ 7.77% (+0.07)
Market Cap $23.56 M
52w High $2.10
52w Low $0.83
Dividend Yield 0%
P/E -1.8
Volume 926.65K
Outstanding Shares 24.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.476M ▼ $-2.205M ▼ 0% $-0.092 ▼ $-2.124M ▲
Q2-2025 $0 $2.993M ▼ $-1.868M ▲ 0% $-0.078 ▲ $-2.993M ▲
Q1-2025 $0 $3.414M ▼ $-3.452M ▲ 0% $-0.16 ▲ $-3.414M ▲
Q4-2024 $0 $5.632M ▲ $-5.176M ▼ 0% $-0.24 ▼ $-5.14M ▼
Q3-2024 $0 $3.119M $-2.602M 0% $-0.12 $-2.958M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $18.316M ▼ $20.938M ▼ $3.457M ▼ $17.481M ▼
Q2-2025 $19.507M ▼ $22.598M ▼ $3.544M ▲ $19.054M ▼
Q1-2025 $20.551M ▼ $24.035M ▼ $3.408M ▼ $20.627M ▼
Q4-2024 $23.609M ▼ $27.687M ▼ $4.098M ▲ $23.589M ▼
Q3-2024 $24.505M $29.797M $3.21M $26.587M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.205M ▼ $-2.295M ▼ $4.162M ▲ $376.107K ▲ $2.191M ▲ $-2.319M ▼
Q2-2025 $-1.868M ▲ $-1.226M ▲ $1.089M ▼ $949.844 ▼ $-161K ▲ $-1.205M ▲
Q1-2025 $-3.452M ▲ $-4.624M ▼ $3.173M ▼ $197K ▼ $-1.254M ▼ $-4.656M ▼
Q4-2024 $-5.176M ▼ $-4.084M ▼ $3.358M ▲ $1.261M ▲ $535K ▲ $-4.153M ▼
Q3-2024 $-2.602M $-2.617M $1.397M $250K $-970K $-2.626M

Five-Year Company Overview

Income Statement

Income Statement Enlivex is still a pure R&D story with no product revenue yet. The income statement shows recurring operating and net losses each year, which is typical for an early‑stage biotech funding clinical trials and research. Losses widened as development spending ramped up and then appear to have edged somewhat lower more recently, suggesting some cost discipline but still a clearly loss‑making profile. Earnings per share remain negative and volatile, reflecting both ongoing cash burn and equity raises over time.

Balance Sheet

Balance Sheet The balance sheet is small and fairly simple. The company has no financial debt, which reduces interest burden and default risk, but also means it relies heavily on equity and other financing to operate. Assets and shareholder equity have trended down from earlier peaks, consistent with cash being spent on R&D faster than it is being replenished. Reported cash balances have fallen from prior years and now look tight, underlining a key risk: the business depends on fresh capital to fund its pipeline. The new digital‑asset‑based treasury strategy adds another layer of complexity and potential volatility to the balance sheet.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting spending on trials, staff, and manufacturing capabilities without any offsetting revenue. Investment spending has been modest, so most of the cash burn is operational rather than tied to large physical assets. Free cash flow is negative each year but relatively stable in scale, pointing to a predictable, ongoing funding need rather than one‑off shocks. The company must repeatedly access capital markets or alternative financing tools to sustain its development plans.

Competitive Edge

Competitive Edge Enlivex operates in a highly competitive biotech space but focuses on a distinctive niche: reprogramming macrophages to restore immune balance. Its lead platform, Allocetra, uses an off‑the‑shelf cell therapy approach with a novel mechanism that aims to modulate, not broadly suppress, the immune system. This first‑in‑class angle, combined with early clinical signals in sepsis and osteoarthritis and a patent estate that stretches well into the future, provides a potential competitive moat. At the same time, the company is still small, pre‑commercial, and going up against much larger players in inflammation and immunology, which means execution, data quality, and partnering will heavily influence its ultimate position in the market.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Enlivex. The Allocetra platform targets macrophages in a way that could be broadly applicable across severe inflammatory and autoimmune diseases, and possibly cancer. Trials so far suggest a favorable safety profile and encouraging signs of benefit in sepsis and knee osteoarthritis, with additional studies planned or underway in psoriatic arthritis and solid tumors. R&D spending is the main driver of losses but also the engine of potential value creation. The company’s strategy is to advance multiple indications off the same core technology, which can be efficient but also concentrates risk in a single platform. Regulatory progress, trial design quality, and the ability to attract partners or non‑dilutive funding are key uncertainties around the R&D story.

Summary

Enlivex is an early‑stage, research‑driven biotech with an entirely development‑focused financial profile: no revenue, recurring losses, and steady cash burn. Its balance sheet is debt‑free but relatively thin, with shrinking cash resources and a growing dependence on external financing; the move into a crypto‑based treasury asset introduces additional risk and complexity. Against that financial fragility stands a scientifically ambitious program built around Allocetra, a differentiated cell therapy platform with promising early data and strong patent protection in areas of substantial unmet need. The company’s future hinges on clinical proof, regulatory alignment, and funding: strong trial results and strategic partnerships could unlock significant opportunity, while setbacks or funding constraints would weigh heavily given the lack of a commercial cushion.

NEWS

November 24, 2025 · 10:00 AM UTC

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Read more

November 24, 2025 · 7:55 AM UTC

Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Read more

November 24, 2025 · 6:40 AM UTC

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Read more

October 28, 2025 · 8:15 AM UTC

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Read more

September 29, 2025 · 8:15 AM UTC

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Read more